Fuse Oncology Inc: Valuation, Funding & Investors
Fuse Oncology Inc is a biotechnology company focused on developing targeted therapies for oncology indications driven by oncogenic fusion proteins and other genetic drivers. The company applies molecular and translational oncology approaches to discover and advance precision medicines intended to selectively target cancer-specific drivers and improve patient outcomes across fusion-driven tumor types.
Leadership & Board
- Current Number of Employees
- 25
- Current LinkedIn Followers
- 3,536
Latest Estimated Valuation
- Total Amount Raised
- $9M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $9M
- Latest Funding Round
- Series A
Company Momentum
PositiveFuse Oncology Inc LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Fuse Oncology Inc had 25 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Fuse Oncology Inc had 3,536 followers as of November 16, 2026. The number of followers increased by 1 (0.03%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| May 21, 2023 | Series A | $8.90M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Cone Health | Series A |
| Northeast Georgia Health System | Series A |
Similar Companies
A snapshot of private companies similar to Fuse Oncology Inc, helping you discover and navigate related company profiles.
Related News and Analysis








